We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve... Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. Show more
Daré Bioscience’s DARE-LARC1 Platform Technology has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases Strategic Process Underway to Explore Partnering...
Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 women Pivotal Phase 3 contraceptive efficacy clinical study of Ovaprene currently enrolling Ovaprene has...
2023 Highlights and Anticipated 2024 Milestones XACIATO™ (clindamycin phosphate) vaginal gel 2% is available by prescription in the United States to treat bacterial vaginosis under license...
U.S. index futures are nearly unchanged in pre-market trading this Thursday. The indexes are on track to close the second consecutive quarter with positive outcomes, in addition to marking the...
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast...
Data to be presented demonstrate increased frequency of sexual events with Sildenafil Cream, 3.6% use in the Phase 2b RESPOND clinical study, as well as improvement in multiple aspects of the...
SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC (SST...
SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced changes in company management which includes the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0286 | -9.26766040181 | 0.3086 | 0.318652 | 0.28 | 490261 | 0.29036052 | CS |
4 | -0.27 | -49.0909090909 | 0.55 | 0.5599 | 0.28 | 498277 | 0.34529624 | CS |
12 | -0.065 | -18.8405797101 | 0.345 | 0.5899 | 0.28 | 454898 | 0.42574233 | CS |
26 | -0.1245 | -30.7787391842 | 0.4045 | 0.5899 | 0.27 | 513617 | 0.37056414 | CS |
52 | -0.74 | -72.5490196078 | 1.02 | 1.1 | 0.27 | 380572 | 0.50295506 | CS |
156 | -1.25 | -81.6993464052 | 1.53 | 2.51 | 0.27 | 1824068 | 1.63634604 | CS |
260 | -0.73 | -72.2772277228 | 1.01 | 3.85 | 0.27 | 1482992 | 1.65701811 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions